Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.40 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 6/20 | 0.40 |
| ▸ | CASP2 | P42575 | 2/20 | 0.40 |
| ▸ | CASP7 | P55210 | 2/20 | 0.40 |
| ▸ | CASP6 | P55212 | 2/20 | 0.40 |
| ▸ | CASP8 | Q14790 | 2/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2312954 | 0.77 | GSK3B (0.39) | KDM4EMAPTCYP3A4GSK3BCASP3 | |
| SCHEMBL4975646 | 0.77 | KDM4E (0.42) | KDM4EMAPTCYP3A4GSK3BCASP3 | |
| SCHEMBL28247275 | 0.77 | GSK3B (0.44) | KDM4EGSK3BCASP3CASP2CASP7 | |
| SCHEMBL10416487 | 0.77 | GSK3B (0.39) | KDM4EMAPTCYP3A4GSK3BCASP3 | |
| SCHEMBL11615864 | 0.77 | KDM4E (0.42) | KDM4EMAPTCYP3A4GSK3BCASP3 | |
| SCHEMBL10879454 | 0.73 | HPGD (0.36) | KDM4EMAPTCYP3A4GSK3BCASP3 | |
| SCHEMBL3908443 | 0.72 | GSK3B (0.48) | KDM4EMAPTCYP3A4GSK3BCASP3 | |
| SCHEMBL166123 | 0.71 | HPGD (0.47) | KDM4EMAPTCYP3A4GSK3BCASP3 | |
| SCHEMBL29206318 | 0.71 | KDM4E (0.41) | KDM4EMAPTCYP3A4ALOX15HPGD | |
| SCHEMBL9242437 | 0.70 | KDM4E (0.47) | KDM4EMAPTCYP3A4ALOX15HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240288773-A1 | METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE, AND COMPOSITION | JSR CORPORATION (JP) | 2024-08-29 | — | — | US | disclosed |
| WO-2023068075-A1 | METHOD FOR PRODUCING SEMICONDUCTOR SUBSTRATE AND RESIST UNDERLAYER FILM-FORMING COMPOSITION | JSR株式会社 | 2023-04-27 | — | — | WO | disclosed |
| CN-106459259-B | N-acetylglucosaminyl sugar chain group-containing compound, carrier compound for drug delivery, preparation, and drug delivery system | 索马龙株式会社 | 2022-07-15 | — | — | CN | disclosed |
| EP-3147300-B1 | N-ACETYLGLUCOSAMINE SUGAR CHAIN GROUP-CONTAINING POLYMER, CARRIER COMPOUND FOR DRUG DELIVERY, DRUG PREPARATION, AND DRUG DELIVERY SYSTEM | SOMAR CORP (JP) | 2020-06-24 | — | — | EP | disclosed |
| US-10471158-B2 | N-acetylglucosamine sugar chain group-containing compound, carrier compound for drug delivery, drug preparation, and drug delivery system | SOMAR CORPORATION (JP) | 2019-11-12 | — | — | US | disclosed |
| US-20170095564-A1 | N-ACETYLGLUCOSAMINE SUGAR CHAIN GROUP-CONTAINING COMPOUND, CARRIER COMPOUND FOR DRUG DELIVERY, DRUG PREPARATION, AND DRUG DELIVERY SYSTEM | SOMAR CORPORATION (JP) | 2017-04-06 | — | — | US | disclosed |
| EP-3147300-A1 | N-ACETYLGLUCOSAMINE SUGAR CHAIN GROUP-CONTAINING COMPOUND, CARRIER COMPOUND FOR DRUG DELIVERY, DRUG PREPARATION, AND DRUG DELIVERY SYSTEM | Somar Corporation (JP) | 2017-03-29 | — | — | EP | disclosed |
| US-20100092445-A1 | Adoptive immune cells for tumor vaccines | SHUKOKAI INCORPORATED (JP) | 2010-04-15 | — | — | US | disclosed |
| US-7655393-B2 | Adoptive immune cells for tumor vaccines | SHUKOKAI INCORPORATED (JP) | 2010-02-02 | — | — | US | disclosed |
| EP-1757680-B1 | Methods for cultivating antigen presenting cells | SHUKOKAI INC (JP) | 2009-09-16 | — | — | EP | disclosed |
| US-20090124706-A1 | CONTACT LENS SOLUTION AND METHOD FOR HYDROPHILIZING CONTACT LENS BY USING THE SAME | TOMEY CO., LTD (JP) | 2009-05-14 | — | — | US | disclosed |
| EP-2042912-A1 | LIQUID AGENT FOR CONTACT LENS AND METHOD FOR HYDROPHILIZING CONTACT LENS BY USING THE SAME | Tomey Co., Ltd. (JP) | 2009-04-01 | — | — | EP | disclosed |
| US-20070286847-A1 | Adoptive Immune Cells For Tumor Vaccines | SHUKOKAI INCORPORATED (JP) | 2007-12-13 | — | — | US | disclosed |
| EP-1757680-A1 | ADOPTIVE IMMUNOCYTE FOR TUMOR VACCINE AND THE LIKE | Shukokai Incorporated (JP) | 2007-02-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124706-A1 | CONTACT LENS SOLUTION AND METHOD FOR HYDROPHILIZING CONTACT LENS BY USING THE SAME | CRYZ, AQP1, CRYAB | KDM4E 1663/4885MAPT 2374/4885CYP3A4 4165/4885 |
| US-20170095564-A1 | N-ACETYLGLUCOSAMINE SUGAR CHAIN GROUP-CONTAINING COMPOUND, CARRIER COMPOUND FOR DRUG DELIVERY, DRUG PREPARATION, AND DRUG DELIVERY SYSTEM | VIM, SLC2A1, CD44 | KDM4E 2948/4885MAPT 214/4885CYP3A4 4444/4885 |
| US-20070286847-A1 | Adoptive Immune Cells For Tumor Vaccines | CD4, PBK, KIT | KDM4E 1160/4885MAPT 1420/4885CYP3A4 3978/4885 |
| US-20100092445-A1 | Adoptive immune cells for tumor vaccines | CD14, TSLP, CD4 | KDM4E 2165/4885MAPT 887/4885CYP3A4 3920/4885 |
| US-10471158-B2 | N-acetylglucosamine sugar chain group-containing compound, carrier compound for drug delivery, drug preparation, and drug delivery system | VIM, SLC2A1, CD44 | KDM4E 2951/4885MAPT 216/4885CYP3A4 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.